Cargando…

Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma

BACKGROUND/AIMS: Sorafenib remains the only approved molecular targeted agent for hepatocellular carcinoma (HCC); however, reliable biomarkers that predict its efficacy are still lacking. The aim of this study was to explore whether cancer stem cell (CSC) markers have a predictive role with regard t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Bo Hyun, Park, Joong-Won, Kim, Jin Sook, Lee, Sook-Kyung, Hong, Eun Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529171/ https://www.ncbi.nlm.nih.gov/pubmed/30600675 http://dx.doi.org/10.5009/gnl18345

Ejemplares similares

Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Kim, Bo Hyun, et al.
Publicado: (2018)

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma
por: Lee, Yeon-Su, et al.
Publicado: (2015)

Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area
por: Shim, Chang Woo, et al.
Publicado: (2017)

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Lee, Sangheun, et al.
Publicado: (2015)

Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma
por: Byun, Jun-Kyu, et al.
Publicado: (2022)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria
por: Cho, Yuri, et al.
Publicado: (2022)

Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells
por: Hong, Tae Ho, et al.
Publicado: (2021)

Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation
por: Lee, Hye Won, et al.
Publicado: (2017)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells
por: Jo, Hanhee, et al.
Publicado: (2020)

Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Kim, Jina, et al.
Publicado: (2022)

Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
por: Kim, Jaewoong, et al.
Publicado: (2020)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era
por: Kim, Nae Yu, et al.
Publicado: (2010)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)

microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression
por: Heo, Mi Jeong, et al.
Publicado: (2014)

The Autophagy-Related Marker LC3 Can Predict Prognosis in Human Hepatocellular Carcinoma
por: Lee, Yoo Jin, et al.
Publicado: (2013)

Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH)
por: Nam, Byung-Ho, et al.
Publicado: (2015)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
por: Seo, Sang Hyun, et al.
Publicado: (2023)

Surveillance for hepatocellular carcinoma: It is time to move forward
por: Kim, Bo Hyun, et al.
Publicado: (2022)

Correction: The Autophagy-Related Marker LC3 Can Predict Prognosis in Human Hepatocellular Carcinoma
por: Lee, Yoo Jin, et al.
Publicado: (2013)

Ruptured Massive Hepatocellular Carcinoma Cured by Transarterial Chemoembolization
por: Lee, Ji Eun, et al.
Publicado: (2020)

Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
por: Cha, Jihye, et al.
Publicado: (2013)

Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Zheng, Liming, et al.
Publicado: (2021)

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer()()
por: Choi, Kyung Hwa, et al.
Publicado: (2018)

Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review
por: Kim, Tae Suk, et al.
Publicado: (2017)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma
por: Kim, Dong-Ho, et al.
Publicado: (2022)

Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
por: Kim, Bo Hyun, et al.
Publicado: (2021)

Predictive Value of Procalcitonin for Bacterial Infection after Transarterial Chemoembolization or Radiofrequency Ablation for Hepatocellular Carcinoma
por: Kang, Seung Ji, et al.
Publicado: (2018)

Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma
por: Paik, Eun Kyung, et al.
Publicado: (2015)

Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review
por: Lim, Dae Hyun, et al.
Publicado: (2020)

The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
por: Cho, Yuri, et al.
Publicado: (2023)

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8stlh4mfd5nttlm6o6iq3hc0t1